Physician profile
Bethany Sleckman
NPI 1861814386
$21,395.02
in general payments reported to CMS, 2019-2025
79 companies · $3,879 in 2025
The $3,879 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $7,746 · 2020: $536 · 2021: $306 · 2022: $2,136 · 2023: $3,512 · 2024: $3,280 · 2025: $3,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,531.95 |
| Education | $139.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $5,098.60 | 2019-2025 | |
| Daiichi Sankyo INC. | $1,674.96 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $1,383.93 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $1,256.15 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $1,053.04 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Novartis Pharmaceuticals Corporation | $761.28 | 2019-2025 | |
| Genentech USA, INC. | $742.71 | 2019-2025 | Lunsumio, Polivy, Columvi |
| E.R. Squibb & Sons, L.L.C. | $729.89 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $723.43 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Seagen INC. | $589.68 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Genzyme Corporation | $543.03 | 2019-2024 | |
| Emd Serono, INC. | $523.23 | 2019-2025 | Bavencio |
| Abbvie INC. | $508.69 | 2019-2025 | Venclexta |
| Amgen INC. | $420.27 | 2019-2025 | Kyprolis, Lumakras, Nplate |
| Regeneron Healthcare Solutions, INC. | $350.90 | 2019-2025 | Libtayo, Lynozyfic |
Show all 75 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $329.30 | 2019-2025 | Trodelvy |
| Tempus Ai, INC | $277.42 | 2024 | |
| Incyte Corporation | $262.82 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $261.57 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.39 | 2019-2025 | Gilotrif |
| Takeda Pharmaceuticals U.S.A., INC. | $207.87 | 2019-2025 | Iclusig, Alunbrig |
| Beigene USA, INC. | $177.96 | 2023-2025 | Tevimbra, Brukinsa |
| Lilly USA, LLC | $173.53 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $169.44 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $166.30 | 2019-2023 | Imbruvica, Epkinly |
| Gen-Probe, INC. | $149.66 | 2023 | Btx |
| Exelixis INC. | $136.75 | 2019-2025 | Cabometyx |
| Beone Medicines USA, INC. | $133.86 | 2025 | Tevimbra, Brukinsa |
| Glaxosmithkline, LLC. | $128.06 | 2022-2025 | Ojjaara, Blenrep, Jemperli |
| Medtronic USA, INC. | $122.12 | 2019 | |
| Tersera Therapeutics LLC | $119.57 | 2023-2025 | Zoladex |
| Karyopharm Therapeutics INC. | $115.43 | 2020-2025 | Xpovio |
| Taiho Oncology, INC. | $112.59 | 2019-2024 | |
| Kite Pharma, INC. | $104.96 | 2020-2025 | Yescarta |
| Rigel Pharmaceuticals, INC. | $103.18 | 2019-2025 | Rezlidhia, Tavalisse, Gavreto |
| Jazz Pharmaceuticals INC. | $99.07 | 2019-2025 | Zepzelca |
| Array Biopharma INC | $97.29 | 2019-2025 | Braftovi, Mektovi, Xalkori |
| Gt Medical Technologies, INC | $90.04 | 2023-2025 | Gammatile, Gammatile |
| Kyowa Kirin, INC. | $84.32 | 2019-2023 | Poteligeo |
| Mylan Institutional INC. | $80.68 | 2019-2022 | |
| Astellas Pharma US INC | $72.85 | 2020-2025 | Vyloy, Xtandi |
| Sumitomo Pharma America, INC. | $65.53 | 2023-2024 | Orgovyx |
| Stemline Therapeutics INC. | $63.98 | 2023-2025 | Orserdu, Elzonris |
| Aveo Pharmaceuticals, INC. | $61.46 | 2022-2024 | Fotivda |
| Servier Pharmaceuticals LLC | $55.29 | 2024 | |
| Mirati Therapeutics, INC. | $54.96 | 2023 | Krazati |
| Adc Therapeutics America, INC. | $48.79 | 2025 | |
| Verastem, INC. | $48.71 | 2019-2020 | |
| Pharmaessentia USA Corporation | $45.33 | 2023-2025 | Besremi |
| Agios Pharmaceuticals, INC. | $37.34 | 2019-2025 | Pyrukynd |
| Morphosys, US INC. | $36.11 | 2022-2023 | Monjuvi |
| Genmab U.S., INC. | $32.37 | 2022-2025 | Tivdak |
| Ipsen Biopharmaceuticals, INC | $32.24 | 2019-2020 | |
| Myovant Sciences INC. | $31.12 | 2022 | |
| Myriad Genetic Laboratories, INC. | $30.41 | 2024 | Myrisk |
| Janssen Pharmaceuticals, INC | $29.15 | 2023-2024 | Xarelto |
| Adaptive Biotechnologies Corporation | $27.16 | 2022 | |
| Novocure INC. | $25.43 | 2024 | Optune |
| Dendreon Pharmaceuticals LLC | $25.07 | 2025 | Provenge |
| Recordati_rare_diseases_inc. | $24.40 | 2025 | Enjaymo |
| Legend Biotech USA INC. | $23.59 | 2025 | Carvykti |
| Pharmacosmos Therapeutics INC. | $23.18 | 2024 | Cosela |
| Springworks Therapeutics, INC. | $22.54 | 2025 | Ogsiveo |
| Geron Corporation | $22.50 | 2025 | Rytelo |
| Secura Bio, INC. | $21.83 | 2022 | |
| Corcept Therapeutics | $20.23 | 2025 | Korlym |
| Azurity Pharmaceuticals, INC. | $17.58 | 2025 | Danziten |
| Apellis Pharmaceuticals, INC. | $17.52 | 2023 | Empaveli |
| Lexicon Pharmaceuticals, INC. | $15.55 | 2019 | |
| Cti Biopharma Corp. | $14.95 | 2023 | Vonjo |
| Epizyme, INC. | $14.73 | 2022 | |
| Tolmar Pharmaceuticals, INC. | $14.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.37 | 2019 | |
| Coherus Oncology, INC. | $14.24 | 2020 | |
| Clovis Oncology, INC. | $9.99 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$7,010.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Sleckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.